An­oth­er myo­statin pro­gram com­busts, but Ac­celeron has plen­ty in the pipeline

Myo­statin in­hibitors — en­gi­neered to build mus­cle and im­prove mo­bil­i­ty in pa­tients — the­o­ret­i­cal­ly make sense for use in pa­tients with mus­cle-wast­ing dis­eases. But the field is lit­tered with fail­ure — and so it was hard­ly sur­pris­ing when Ac­celeron, which years ago scrapped a myo­statin pro­gram it had part­nered with Shire, dis­closed an­oth­er flopped myo­statin drug on Mon­day.

Ac­celeron’s drug, ACE-083, was be­ing test­ed in a mid-stage study in pa­tients with Char­cot-Marie-Tooth dis­ease (CMT), a group of in­her­it­ed dis­or­ders that cause nerve dam­age and are char­ac­ter­ized by small­er, weak­er mus­cles.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.